Centrilobular emphysema combined with pulmonary fibrosis results in improved survival

Nevins W Todd; Jean Jeudy; Sachin Lavania; Teri J Franks; Jeffrey R Galvin; Janaki Deepak; Edward J Britt; Sergei P Atamas

doi:10.1186/1755-1536-4-6

Centrilobular emphysema combined with pulmonary fibrosis results in improved survival

Fibrogenesis Tissue Repair. 2011 Feb 15;4(1):6. doi: 10.1186/1755-1536-4-6.

Authors

Nevins W Todd¹, Jean Jeudy, Sachin Lavania, Teri J Franks, Jeffrey R Galvin, Janaki Deepak, Edward J Britt, Sergei P Atamas

Affiliation

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. ntodd@medicine.umaryland.edu.

Abstract

Background: We hypothesized that, in patients with pulmonary fibrosis combined with emphysema, clinical characteristics and outcomes may differ from patients with pulmonary fibrosis without emphysema. We identified 102 patients who met established criteria for pulmonary fibrosis. The amount of emphysema (numerical score) and type of emphysema (centrilobular, paraseptal, or mixed) were characterized in each patient. Clinical characteristics, pulmonary function tests and patient survival were analysed.

Results: Based on the numerical emphysema score, patients were classified into those having no emphysema (n = 48), trivial emphysema (n = 26) or advanced emphysema (n = 28). Patients with advanced emphysema had a significantly higher amount of smoking in pack/years than patients with no emphysema or trivial emphysema (P < 0.0001). Median survival [1st, 3rd quartiles] of patients with advanced emphysema was 63 [36, 82] months compared to 29 [18, 49] months in patients without emphysema and 32 [19, 48] months in patients with trivial emphysema (P < 0.001). Median forced vital capacity (FVC) and total lung capacity (TLC) were higher in the advanced emphysema group compared to patients with no emphysema (P < 0.01 and P < 0.001, respectively), whereas median DLCO did not differ among groups and was overall low. Within the advanced emphysema group (n = 28), further characterization of the type of emphysema was performed and, within these subgroups of patients, survival was 75 [58, 85] months for patients with centrilobular emphysema, 75 [48, 85] months for patients with mixed centrilobular/paraseptal emphysema, and 24 [22, 35] months for patients with paraseptal emphysema (P < 0.01). Patients with advanced paraseptal emphysema had similar survival times to patients without emphysema.

Conclusions: Patients with pulmonary fibrosis combined with advanced centrilobular or mixed emphysema have an improved survival compared with patients with pulmonary fibrosis without emphysema, with trivial emphysema or with advanced paraseptal emphysema.